Tuesday, July 18, 2017 (HealthDay News)-Nerlynx (neratinib) approved by the U.S. Food and Drug Administration to help prevent HER2-positive breast cancer From returning.
This is the first drug designed to prevent a recurrence of HER2-positive breast cancer, A genetic form of the disease that is particularly aggressive and can spread to other parts of the body, officials said in a news release.
This drug is intended for what is known as diastolic adjuvant therapy-given after the first treatment to further reduce its risk cancer I will be back.
breast cancer Is the most common form of cancer In the United States, the FDA said. According to US citizens, the disease is estimated to be diagnosed in more than 250,000 women this year, and more than 46,000 can die from the disease. cancer Laboratory.
Nerlynx, in class Drug Designed to block enzymes that promote cancer cell growth, it was evaluated in clinical trials in more than 2,800 early-stage HER2-positive individuals. breast cancer Those who have completed treatment at chemical treatment drag Trastuzumab.. Two years later, 94.2% of users had no recurrence of the cancer, compared to 91.9% of users treated with inactive placebo.
The most common side effects of Nerlynx are: diarrhea, nausea, stomach ache, Malaise, vomiting, rash And swelling of the mouth.Those taking the drug should be given anti-drugdiarrhea dosage Loperamide During the first 50 days of use, the FDA advised.
A woman Pregnant Authorities added that Nerlynx should not be taken because it can harm the developing foetation.
Nerlynx approval has been granted to Los Angeles-based Puma Biotechnology.
Copyright © 2017 Health Day. all rights reserved.
Source: July 17, 2017, News Release, US Food and Drug Administration
Nerlynx Approves to Help Prevent Breast Cancer Recurrence
Source link Nerlynx Approves to Help Prevent Breast Cancer Recurrence